News Archive | Page 11 of 23 | Lexaria Bioscience Corp.

News

Lexaria raises US$1M from Warrant Exercise

Kelowna, BC / May 19, 2017 / Lexaria Bioscience Corp (OTCQB:LXRP) (CSE:LXX) (the "Company" or "Lexaria") announces it has received US$970,230.05 from the exercise of warrants previously granted. The stock…

Lexaria Featured on Television

Kelowna, BC / May 18, 2017 / Lexaria Bioscience Corp. (OTCQB:LXRP) (CSE:LXX) (the "Company" or "Lexaria") is one of five companies featured on a special BTV episode exploring burgeoning cannabis…

Lexaria Announces Research on Nonsteroidal Anti-Inflammatory Drugs

Kelowna, BC / May 10, 2017 / Lexaria Bioscience Corp (OTCQB:LXRP) (CSE:LXX) (the “Company”, “Lexaria”) announces plans for research and formulation development (“R&D”) on nonsteroidal anti-inflammatory drugs (“NSAIDs”) utilizing its…

Lexaria Announces R&D on Nicotine

Kelowna, BC / May 4, 2017 / Lexaria Bioscience Corp (OTCQB:LXRP) (CSE:LXX) (the “Company”, “Lexaria”) is announcing new plans to commence nicotine absorption research beginning in the summer of 2017,…

Lexaria and Neutrisci Enter Cannabinoid Joint Venture

Kelowna, BC / April 10, 2017 / Lexaria Bioscience Corp (OTCQB:LXRP) (CSE:LXX) (the "Company") and Neutrisci International Inc (“Neutrisci”) (TSX-V:NU, OTCQB:NRXCF, Frankfurt-1N9) have completed and signed the previously announced joint venture…

Lexaria Bioscience Closes Brokered Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES KELOWNA, BRITISH COLUMBIA, April 3, 2017 – Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) (the…